Literature DB >> 7966566

Comparison of mucosal and systemic humoral immune responses and subsequent protection in mice orally inoculated with a homologous or a heterologous rotavirus.

N Feng1, J W Burns, L Bracy, H B Greenberg.   

Abstract

Rotaviruses are the single most important cause of severe diarrhea in young children worldwide, and vaccination is probably the most effective way to control the disease. Most current live virus vaccine candidates are based on the host range-restricted attenuation of heterologous animal rotaviruses in humans. The protective efficacy of these vaccine candidates has been variable. To better understand the nature of the heterologous rotavirus-induced active immune response, we compared the differences in the mucosal and systemic immune responses generated by heterologous (nonmurine) and homologous (murine) rotaviruses as well as the ability of these infections to produce subsequent protective immunity in a mouse model. Sucking mice were orally inoculated with a heterologous simian or bovine rotavirus (strain RRV or NCDV) or a homologous murine rotavirus (wild-type or tissue culture-adapted) strain EHP at various doses. Six weeks later, mice were challenged with a virulent murine rotavirus (wild-type strain ECW) and the shedding of viral antigen in feces was quantitated. Levels of rotavirus-specific serum immunoglobulin G (IgG) and fecal IgA prior to challenge were measured and correlated with subsequent viral shedding or protection. Heterologous rotavirus-induced active protection was highly dependent on the strain and dose of the virus tested. Mice inoculated with a high dose (10(7) PFU per mouse) of RRV were completely protected, while the protection was diminished in animals inoculated with NCDV or lower doses of RRV. The ability of a heterologous rotavirus to stimulate a detectable intestinal IgA response correlated with the ability of the virus to generate protective immunity. Serum IgG titer did not correlate with protection. Homologous rotavirus infection, on the other hand, was much more efficient at inducing both mucosal and systemic immune responses as well as protection regardless of the virulence of the virus strain or the size of the immunizing dose.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7966566      PMCID: PMC237238          DOI: 10.1128/JVI.68.12.7766-7773.1994

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  14 in total

1.  Reassortant rotaviruses as potential live rotavirus vaccine candidates.

Authors:  K Midthun; H B Greenberg; Y Hoshino; A Z Kapikian; R G Wyatt; R M Chanock
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

2.  Comparison of VP4 and VP7 of five murine rotavirus strains.

Authors:  S J Dunn; J W Burns; T L Cross; P T Vo; R L Ward; M Bremont; H B Greenberg
Journal:  Virology       Date:  1994-09       Impact factor: 3.616

3.  Development of an adult mouse model for studies on protection against rotavirus.

Authors:  R L Ward; M M McNeal; J F Sheridan
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

4.  Reactogenicity and immunogenicity of a high-titer rhesus rotavirus-based quadrivalent rotavirus vaccine.

Authors:  J Flores; I Perez-Schael; M Blanco; A M Rojas; E Alfonzo; I Crespo; W Cunto; A L Pittman; A Z Kapikian
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

5.  Clinical trials of live oral rotavirus vaccines: the Finnish experience.

Authors:  T Vesikari
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

6.  Murine rotavirus genes encoding outer capsid proteins VP4 and VP7 are not major determinants of host range restriction and virulence.

Authors:  R L Broome; P T Vo; R L Ward; H F Clark; H B Greenberg
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

Review 7.  Development of candidate rotavirus vaccines.

Authors:  R F Bishop
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

8.  Fecal antibody responses to symptomatic and asymptomatic rotavirus infections.

Authors:  D O Matson; M L O'Ryan; I Herrera; L K Pickering; M K Estes
Journal:  J Infect Dis       Date:  1993-03       Impact factor: 5.226

Review 9.  An update on the "Jennerian" and modified "Jennerian" approach to vaccination of infants and young children against rotavirus diarrhea.

Authors:  A Z Kapikian; T Vesikari; T Ruuska; H P Madore; C Christy; R Dolin; J Flores; K Y Green; B L Davidson; M Gorziglia
Journal:  Adv Exp Med Biol       Date:  1992       Impact factor: 2.622

10.  Serotypic similarity and diversity of rotaviruses of mammalian and avian origin as studied by plaque-reduction neutralization.

Authors:  Y Hoshino; R G Wyatt; H B Greenberg; J Flores; A Z Kapikian
Journal:  J Infect Dis       Date:  1984-05       Impact factor: 5.226

View more
  67 in total

1.  Rotavirus virus-like particles administered mucosally induce protective immunity.

Authors:  C M O'Neal; S E Crawford; M K Estes; M E Conner
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Serum IgG mediates mucosal immunity against rotavirus infection.

Authors:  Larry E Westerman; Harold M McClure; Baoming Jiang; Jeffrey W Almond; Roger I Glass
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-09       Impact factor: 11.205

3.  Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion.

Authors:  Blaise Corthésy; Yann Benureau; Clémentine Perrier; Cynthia Fourgeux; Nathalie Parez; Harry Greenberg; Isabelle Schwartz-Cornil
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

4.  Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection.

Authors:  Nathalie Parez; Cynthia Fourgeux; Ali Mohamed; Catherine Dubuquoy; Mathieu Pillot; Axelle Dehee; Annie Charpilienne; Didier Poncet; Isabelle Schwartz-Cornil; Antoine Garbarg-Chenon
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  Differential requirements for T cells in viruslike particle- and rotavirus-induced protective immunity.

Authors:  Sarah E Blutt; Kelly L Warfield; Mary K Estes; Margaret E Conner
Journal:  J Virol       Date:  2008-01-09       Impact factor: 5.103

6.  Characterization of in vivo anti-rotavirus activities of saponin extracts from Quillaja saponaria Molina.

Authors:  Ka Ian Tam; Michael R Roner
Journal:  Antiviral Res       Date:  2011-04-23       Impact factor: 5.970

Review 7.  Immune responses to rotavirus infection and vaccination and associated correlates of protection.

Authors:  Ulrich Desselberger; Hans-Iko Huppertz
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

8.  Immune mediators of rotavirus antigenemia clearance in mice.

Authors:  Glendie Marcelin; Amber D Miller; Sarah E Blutt; Margaret E Conner
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

9.  Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus.

Authors:  T Muster; B Ferko; A Klima; M Purtscher; A Trkola; P Schulz; A Grassauer; O G Engelhardt; A García-Sástre; P Palese
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

10.  Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles.

Authors:  S C Chen; D H Jones; E F Fynan; G H Farrar; J C Clegg; H B Greenberg; J E Herrmann
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.